Helicobacter pylori testing is essential for diagnosing one of the world's most common bacterial infections, a pathogen strongly linked to chronic gastritis, peptic ulcer disease, and gastric cancer. This guide explains the invasive and non-invasive testing methods, sample types, detection principles, quality standards, and clinical applications of H. pylori detection performed by hospital clinical laboratories and accredited third-party laboratories.
Technical Overview
Helicobacter pylori (H. pylori) is a spiral-shaped, Gram-negative, microaerophilic bacterium that colonizes the mucus layer of the human gastric mucosa. It is one of the most widespread infections worldwide, affecting an estimated 40 to 50 percent of the global population, and is transmitted primarily through oral-oral and fecal-oral routes. Persistent infection causes chronic gastritis and is the leading cause of peptic ulcer disease.
The International Agency for Research on Cancer (IARC) classifies H. pylori as a Group 1 carcinogen because infection is strongly associated with gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Because most infections are asymptomatic yet treatable, reliable laboratory detection and confirmation of eradication are central to gastric cancer prevention strategies. H. pylori testing is performed by hospital clinical laboratories and accredited third-party laboratories under quality management systems compliant with ISO 15189 (Medical laboratories — Requirements for quality and competence), with specimen handling conducted in accordance with ISO 15190 and GB 19489 general biosafety requirements for laboratories.
Common clinical indications for testing include:
- Active or past peptic ulcer disease or complications
- Early gastric neoplasia resected by endoscopy
- Dyspepsia in test-and-treat strategies
- Unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura
- First-degree relatives of patients with gastric cancer
- Confirmation of eradication after antimicrobial therapy
Testing Samples
Appropriate specimen collection, transport, and storage directly affect the accuracy of H. pylori detection. The principal sample types are described below.
Gastric Biopsy Tissue
Biopsies are obtained during upper gastrointestinal endoscopy, typically two specimens each from the antrum and the corpus as recommended by the updated Sydney System. Fresh tissue can be used immediately for rapid urease testing, fixed in formalin for histopathology, transported in specialized medium for culture (delivered to the laboratory within a few hours and kept refrigerated), or frozen for molecular testing.
Exhaled Breath Samples
For the urea breath test, exhaled breath is collected in dedicated gas-collection bags or tubes before and 15 to 30 minutes after ingestion of a 13C- or 14C-labeled urea substrate. The paired samples are analyzed together to calculate the delta-over-baseline value, which reflects intragastric urease activity.
Stool Specimens
Fresh stool is collected in a clean, sealed container for antigen detection. Specimens may be stored at 2 to 8 °C for one to three days or frozen for longer periods. Contamination with urine or water and repeated freeze-thaw cycles should be avoided because they can degrade test performance.
Serum and Whole Blood Samples
Venous blood collected into plain or separator tubes is centrifuged to obtain serum for antibody measurement. Finger-prick whole blood can also be used with rapid point-of-care immunochromatographic devices. Serological testing requires no fasting or special preparation.
Testing Items
Depending on the sample type and clinical purpose, H. pylori testing panels typically include the following items:
- H. pylori stool antigen (qualitative detection)
- H. pylori serum antibodies (IgG, IgA, IgM)
- 13C / 14C urea breath test delta-over-baseline (DOB) value
- H. pylori DNA qualitative detection by real-time PCR
- Bacterial isolation, identification, and confirmation of typical colonies
- Antimicrobial susceptibility testing for clarithromycin, levofloxacin, amoxicillin, tetracycline, and metronidazole
- Resistance-associated mutation detection (23S rRNA, gyrA gene mutations)
- Virulence factor genotyping (CagA, VacA)
Testing Methods
H. pylori detection methods are divided into invasive techniques that require endoscopic biopsy and non-invasive techniques performed on breath, stool, or blood. Method selection depends on the clinical context, pre-test medication exposure, local prevalence, and whether assessment of antibiotic resistance is required.
Urea Breath Test (UBT)
The patient ingests urea labeled with the stable isotope carbon-13 or the radioisotope carbon-14. If H. pylori is present, its abundant urease enzyme hydrolyzes the substrate, releasing labeled carbon dioxide that is absorbed into the bloodstream and exhaled. 13C enrichment is quantified by isotope-ratio mass spectrometry or infrared spectroscopy, while 14C is measured by scintillation counting. With sensitivity and specificity exceeding 95 percent, the UBT is widely regarded as the non-invasive reference method and is the preferred test for confirming eradication. Proton pump inhibitors should be discontinued for at least two weeks, and antibiotics or bismuth for at least four weeks, before testing to avoid false-negative results.
Stool Antigen Test
Monoclonal or polyclonal antibody-based enzyme immunoassays (ELISA) and lateral-flow immunochromatographic assays detect H. pylori antigens shed into feces. The monoclonal ELISA format achieves approximately 94 percent sensitivity and 97 percent specificity. Because it reflects active infection, the stool antigen test is suitable both for primary diagnosis and for post-treatment follow-up.
Serological Antibody Testing
ELISA, chemiluminescent immunoassay, and Western blot methods measure serum IgG against H. pylori. Serology is unaffected by recent antibiotic or acid-suppressive use and remains reliable in patients with bleeding ulcers or severe gastric atrophy, where urease-based tests lose accuracy. However, antibodies persist for years after eradication, so serology cannot distinguish active from past infection and should not be used to confirm cure.
Rapid Urease Test (RUT)
A gastric biopsy is immersed in a medium containing urea and a pH indicator. Urease released from infected tissue hydrolyzes the urea, raises the pH, and produces a visible color change within minutes to several hours. RUT is inexpensive and highly specific, and a positive result allows treatment decisions to be made during the same endoscopy visit.
Histopathology
Formalin-fixed biopsies are stained with hematoxylin-eosin together with special stains such as Giemsa, Warthin-Starry silver, or immunohistochemistry to visualize the bacteria. Histology offers the unique advantage of simultaneously grading inflammation and detecting atrophy, intestinal metaplasia, and dysplasia according to the updated Sydney System, thereby supporting gastric cancer risk stratification.
Bacterial Culture and Susceptibility Testing
Culture remains the definitive reference method. Specimens are inoculated onto selective agar and incubated at 35 to 37 °C under microaerophilic conditions (approximately 5 percent oxygen, 10 percent carbon dioxide, 85 percent nitrogen) for three to seven days. Colonies are confirmed by typical morphology, positive oxidase, catalase, and urease reactions, and mass spectrometric identification. Isolates undergo minimum inhibitory concentration (MIC) determination by agar dilution or gradient methods, with results interpreted using internationally recognized clinical breakpoints such as EUCAST or CLSI criteria. This enables susceptibility-guided therapy in regions with high clarithromycin or levofloxacin resistance.
Molecular Testing (PCR and qPCR)
Real-time fluorescent PCR assays targeting genes such as ureA, glmM, or 16S and 23S rRNA detect H. pylori DNA in biopsy tissue, gastric juice, or stool with very high analytical sensitivity. Multiplex assays can simultaneously identify point mutations conferring clarithromycin resistance (23S rRNA A2142G and A2143G) and quinolone resistance (gyrA mutations) within hours, supporting personalized treatment without the need for culture.
Applications
H. pylori testing supports clinical care and public health across multiple settings:
- Diagnosis of H. pylori infection in patients with dyspepsia, peptic ulcer disease, or early gastric neoplasia
- Confirmation of eradication at least four weeks after completion of therapy
- Screening and family-based testing of first-degree relatives of gastric cancer patients
- Antimicrobial resistance surveillance to guide regional and individualized treatment regimens
- Epidemiological surveys measuring population prevalence and transmission patterns
- Diagnosis and monitoring of gastric MALT lymphoma associated with infection
- Research applications including vaccine studies, virulence genotyping, and host-pathogen interaction analyses
FAQ
Q1: Which test is the most accurate?
A: No single test is perfect. The 13C urea breath test and the monoclonal stool antigen test each exceed 95 percent sensitivity and specificity for active infection, while bacterial culture remains the definitive reference method and additionally provides susceptibility data. The test should be chosen according to the clinical situation.
Q2: Why must certain medications be stopped before testing?
A: Proton pump inhibitors, H2-receptor blockers, antibiotics, and bismuth compounds suppress bacterial load and urease activity, causing false-negative results. Current guidelines recommend stopping proton pump inhibitors for at least two weeks and antibiotics or bismuth for at least four weeks before urea breath, stool antigen, rapid urease, histology, or culture testing.
Q3: Is the breath test safe for children and pregnant women?
A: The 13C-urea breath test uses a stable, non-radioactive isotope and is safe for children as well as pregnant or breastfeeding women. The 14C test involves a trace amount of radioactivity and is generally avoided in these populations.
Q4: Does a positive antibody blood test mean there is an active infection?
A: Not necessarily. IgG antibodies can remain detectable for years after the bacteria have been eliminated. A positive serology result indicates past or current exposure and should be confirmed with an active-infection test, such as the urea breath test or stool antigen test, before treatment is initiated.
Q5: How soon after treatment should eradication be confirmed?
A: Follow-up testing must be performed at least four weeks after finishing antibiotic therapy, and ideally while off acid-suppressive medication, to avoid false-negative results.
Q6: Can testing determine which antibiotics will be effective?
A: Yes. Culture-based antimicrobial susceptibility testing or PCR detection of resistance mutations can identify clarithromycin and levofloxacin resistance, allowing clinicians to select an effective regimen, particularly in areas where resistance rates exceed 15 percent.
